Latest news with #VenousThromboembolism


Medscape
20 hours ago
- Health
- Medscape
Higher VTE Risk in Cushing vs Other Pituitary Tumours
TOPLINE: Patients with Cushing disease faced a substantially higher risk for venous thromboembolism (VTE) than those with non-functioning pituitary adenomas or acromegaly, with the risk peaking around the time of diagnosis and surgery. A history of diabetes also remained an independent risk factor for VTE. METHODOLOGY: Researchers in England conducted a multicentric retrospective cohort study to evaluate the risk for VTE in patients with Cushing disease compared with that in those with other pituitary tumours. They analysed 827 patients (median age at diagnosis, 54 years; 51.6% men), including 107 with Cushing disease, 502 with non-functioning pituitary adenomas, and 218 with acromegaly. Data on VTE events spanning 4 years prior to the diagnosis of pituitary adenoma through the last follow-up were obtained from patient records, with a median follow-up duration of 13.4 years; if multiple VTE events occurred in a single individual, only the first event was analysed. Demographic and clinical data such as sex, date and age at tumour diagnosis, date of surgery for the pituitary tumour, history of diabetes or impaired glucose tolerance, and specific details of VTE events were also extracted from patient records. TAKEAWAY: VTE events were significantly more common in patients with Cushing disease than in those with non-functioning pituitary adenomas (odds ratio [OR], 21.05; P < .001) or acromegaly (OR, 4.48; P = .002). In the adjusted analysis, Cushing disease was associated with a markedly higher risk for VTE events than non-functioning pituitary adenomas (hazard ratio [HR], 46.87; P < .001); acromegaly also conferred an elevated risk (HR, 6.96; P = .007). Diabetes or impaired glucose tolerance was independently associated with an increased risk for VTE (HR, 3.48; P = .008). Among 12 VTE events that occurred in patients with Cushing disease, eight occurred within 1 year before or after the diagnosis of the condition; moreover, four events occurred within 45 days post-transsphenoidal surgery. IN PRACTICE: "[The study] findings provide further evidence of the need for rigorous thromboprophylaxis in patients with CD [Cushing disease] from the time of diagnosis and subsequently throughout the perioperative period," the authors wrote. SOURCE: This study was led by Kristina Isand, University of Tartu, Tartu, Estonia. It was published online on July 03, 2025, in the European Journal of Endocrinology. LIMITATIONS: The retrospective design of the study may have introduced potential bias. Data on confounding factors, such as oral contraceptive use, pregnancy history, and family history of VTE, were not collected. The small number of VTE events further limited the complexity of multivariable modelling, particularly in subgroup analyses. DISCLOSURES: This study did not receive any funding. One author reported serving on the editorial board of the European Journal of Endocrinology. The other authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Associated Press
15-05-2025
- Health
- Associated Press
National Blood Clot Alliance (NBCA) Designates Two AdventHealth Hospitals as Centers of Excellence for VTE Care
Recognition Highlights AdventHealth's Commitment to Exceptional Care in Blood Clot Prevention, Diagnosis, and Treatment 'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents.'— Dr. Arkadiy Kheyfits, AdventHealth Palm Coast and Palm Coast Parkway PALM COAST, FL, UNITED STATES, May 15, 2025 / / -- The National Blood Clot Alliance (NBCA) is proud to announce the designation of AdventHealth Palm Coast and AdventHealth Palm Coast Parkway as NBCA Venous Thromboembolism (VTE) Centers of Excellence™. These hospitals are the first in the AdventHealth system and the first in Northeast Florida to earn this prestigious recognition for their commitment to delivering exceptional, patient-centered care in the prevention, diagnosis, and treatment of blood clots. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a significant public health concern in the United States. According to the Centers for Disease Control and Prevention (CDC), up to 900,000 people in the U.S. are affected by VTE each year, and as many as 100,000 die as a result. Despite these alarming numbers, VTE remains underdiagnosed and undertreated—highlighting the importance of comprehensive, multidisciplinary approaches to care. 'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents' said Dr. Arkadiy Kheyfits, Interventional Radiologist at AdventHealth Palm Coast and Palm Coast Parkway.' I believe AdventHealth Palm Coast and Palm Coast Parkway are leaders in this space, and I am excited to continue improving our care and prevention pathways.' As NBCA VTE Centers of Excellence™, both AdventHealth Palm Coast campuses join a growing network of leading institutions recognized for advancing VTE care through clinical excellence, innovation, and a commitment to education and prevention. This expanding network includes distinguished centers such as Corewell Health West Butterworth Hospital in Grand Rapids, MI, and Ascension Sacred Heart Hospital in Pensacola, FL. 'NBCA VTE Centers of Excellence™ are setting a new standard in how we approach VTE—from acute management to long-term prevention,' said Erin VanDyke, PA-C, Vice President of the NBCA COE Program. 'The teams at AdventHealth Palm Coast and Palm Coast Parkway exemplify the mission of this program through their multidisciplinary collaboration, dedication to best practices, and focus on patient outcomes. We are proud to welcome them as the first designated Centers of Excellence in both the AdventHealth system and Northeast Florida.' The NBCA COE program aims to improve outcomes and save lives by partnering with institutions that embrace innovative, evidence-based, and patient-focused strategies to prevent and treat VTE. To learn more about the NBCA VTE Centers of Excellence™ program, visit About the National Blood Clot Alliance (NBCA) Established in 2003, the National Blood Clot Alliance (NBCA) is the nation's leading nonprofit, patient advocacy organization dedicated to advancing the prevention, early diagnosis, and treatment of life-threatening blood clots. Through a strategic focus on education, advocacy, and research, NBCA empowers patients and families, supports healthcare professionals, and drives national efforts to improve awareness, detection, and outcomes related to VTE. NBCA leads initiatives that strengthen the standard of care and foster innovation in VTE prevention and treatment across the United States. About AdventHealth AdventHealth is a connected network of care that helps people feel whole – body, mind and spirit. More than 100,000 team members across a national footprint provide whole-person care to nearly nine million people annually through more than 2,000 care sites that include hospitals, physician practices, ambulatory surgery centers, outpatient clinics, home health agencies, hospice centers, the AdventHealth app and more. Our wholistic approach to improving the health and prosperity of our communities is inspired by our mission to extend the healing ministry of Christ. For the latest news about AdventHealth, visit Tarin Patrikis National Blood Clot Alliance [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.